BMI-1 Antibody, anti-human, REAfinity™
Synonyms: BMI1, FLVI2/BMI1, PCGF4, RNF51, flvi-2/bmi-1
RECOMBINANT
Bioz Star94/100 Bioz rating
3 Citations1 Image
Clone:
REA438 | P51-311
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for BMI-1 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
FITC
PE
Vio B515
Vio Bright V423
Description:
Human HeLa cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-BMI-1 antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.
Intracellular flow cytometry applications
APC
FITC
PE
Vio B515
Vio Bright V423
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-124-301, 130-124-254
Description:
Human HeLa cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-BMI-1 antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-124-301, 130-124-254
Testing grade:
Product data and images for BMI-1 Antibody, anti-human, REAfinity™
Figure 1

Human HeLa cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-BMI-1 antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Specifications for BMI-1 Antibody, anti-human, REAfinity™
Overview

Clone REA438 recognizes the human B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) antigen, which is also known as polycomb group RING finger protein 4 (PCGF4). BMI-1 is a member of the polycomb group of transcription repressors that was initially identified as an oncogene cooperating with c-myc in a murine model of lymphoma. Both, hematopoietic stem cells (HSCs) and neuronal stem cells, express high levels of BMI-1. It has been shown that BMI-1 is necessary for efficient self-renewing cell divisions of adult HSCs as well as adult peripheral and central nervous system neural stem cells, but that it is less critical for the generation of differentiated progeny. BMI-1 causes neoplastic proliferation when overexpressed in lymphocytes.

Additional information: Clone REA438 displays negligible binding to Fc receptors.

Alternative names

BMI1, FLVI2/BMI1, PCGF4, RNF51, flvi-2/bmi-1

Detailed product information

Technical specifications

Clone
REA438
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
BMI-1
Molecular mass of antigen [kDa]
37
Distribution of antigen
stem cells, hematopoietic stem and progenitor cells
Entrez Gene ID
RRID
AB_2876920, AB_2876919, AB_2889415, AB_2889412, AB_2889413, AB_2889414

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for BMI-1 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?